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Abstract
Background: Administration of a single physiological dose of 17beta-estradiol (E2:40 microg/kg) to the ovariectomized
immature rat rapidly induces uterine growth and remodeling. The response is characterized by changes in endometrial
stromal architecture during an inflammatory-like response that likely involves activated matrix-metalloproteinases
(MMPs). While estrogen is known as an inducer of endometrial growth, its role in specific expression of MMP family
members in vivo is poorly characterized. E2-induced changes in MMP-2, -3, -7, and -9 mRNA and protein expression
were analyzed to survey regulation along an extended time course 0-72 hours post-treatment. Because E2 effects
inflammatory-like changes that may alter MMP expression, we assessed changes in tissue levels of TNF-alpha and MCP-
1, and we utilized dexamethasone (600 microg/kg) to better understand the role of inflammation on matrix remodeling.
Methods: Ovariectomized 21 day-old female Sprague-Dawley rats were administered E2 and uterine tissues were
extracted and prepared for transmission electron microscopy (TEM), mRNA extraction and real-time RT-PCR, protein
extraction and Western blot, or gelatin zymography. In inhibitor studies, pretreatment compounds were administered
prior to E2 and tissues were harvested at 4 hours post-hormone challenge.
Results: Using a novel TEM method to quantitatively assess changes in stromal collagen density, we show that E2-
induced matrix remodeling is rapid in onset (< 1 hour) and leads to a 70% reduction in collagen density by 4 hours. Matrix
remodeling is MMP-dependent, as pretreatment with batimastat ablates the hormone effect. MMP-3, -7, and -9 and
inflammatory markers (TNF-alpha and MCP-1) are transiently upregulated with peak expression at 4 hours post-E2
treatment. MMP-2 expression is increased by E2 but highest expression and activity occur later in the response (48
hours). Dexamethasone inhibits E2-modulated changes in collagen density and expression of MMPs although these effects
are variable. Dexamethasone upregulates MMP-3 mRNA but not protein levels, inhibiting E2-induced upregulation of
MMP-7, and -9, and MCP-1 mRNA and protein but not inhibiting the hormone-induced increase in TNF-alpha mRNA.
Conclusion: The data demonstrate that E2-regulated endometrial remodeling is rapid in onset (<1 hour) and peak
expression of MMPs and inflammatory mediators correlates temporally with the period of lowest stromal collagen
density during uterine tissue hypertrophy.
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Background
The ovariectomized (OVX) immature rat has been used
extensively to study hormone-specific regulatory proc-
esses in the mammalian uterus. In this model, administra-
tion of a single physiological dose of 17β-estradiol (E2; 40
μg/kg) induces a biphasic uterine growth response, char-
acterized by rapid tissue hypertrophy followed by hyper-
plasia. The early hypertrophic growth phase peaks
approximately 4 h after E2 administration and is character-
ized by extensive collagen matrix remodeling of the
endometrial stroma [1]. The controlled degradation and
repair of the stromal extracellular matrix is a necessary
component of a variety of normal reproductive processes,
including endometrial cycling [2-4], implantation [5],
and pregnancy [6], and involves regulated expression and
activity of proteolytic enzymes including the matrix met-
alloproteinases (MMPs) by steroid hormones. Hormone-
induced regulation of MMP expression is complex and
appears to involve cell-type specific changes in expression
of local paracrine mediators as well as direct and indirect
effects on mRNA transcription via activated receptors.
Matrix metalloproteinases comprise a family of related
enzymes, each of which can degrade at least one compo-
nent of the extracellular matrix, consisting of numerous
types of collagen, gelatin, elastin, fibronectin, and lam-
inin, among others [reviewed in [7]. In addition, MMPs
have been shown to act on non-matrix substrates by mod-
ifying and/or activating other MMPs [8-10], growth fac-
tors [11], cytokines [12,13], chemokines [14,15], and
other growth regulators that are matrix-bound or present
on the cell surface [16,17]. Expression is controlled at the
level of transcription in response to proto-oncogenes and
exogenous signals, including hormones [18,19],
cytokines [20,21], and growth factors [22]. At the post-
translational level, MMPs in the extracellular space are
regulated by endogenous inhibitors, including a group of
tissue-derived inhibitors termed TIMPs (tissue inhibitors
of metalloproteinases) [7,23]. Furthermore, most MMPs
are secreted as inactive proenzymes (proMMPs), also
known as zymogens, requiring the cleavage of a specific
propeptide domain for activation [24]. Although the
mechanisms governing proMMP activation are not com-
pletely understood, evidence suggests that inflammatory
mediators function to regulate MMP activity in the extra-
cellular space [4,9,20,25].
Many studies have shown that administration of physio-
logical dose level of estrogen to the immature or OVX
rodent induces an acute inflammatory-like response,
including the coordinated influx of blood-born macro-
phages, neutrophils, and eosinophils into the uterine
endometrial stroma [26-31]. The pro-inflammatory and
growth effects of E2 are antagonized by co-administration
of anti-inflammatory agents, including the synthetic glu-
cocorticoid dexamethasone [32-36] and the steroid hor-
mone progesterone (P4) [37]. Evidence suggests that the
estrogen-mediated infiltration of inflammatory cells into
the endometrial stroma may lead to activation of extracel-
lular proMMPs, which have been shown to colocalize
with leukocytes in the mouse [38] and human [29]
endometrium. Proteinases released by inflammatory cells,
including tryptase, chymase, leukocyte elastase, and
MMPs, have been shown to activate proMMPs in culture
[8,9,39,40], while metabolites and oxidants generated by
inflammatory cells may also regulate MMP activation [41-
43]. These studies and others suggest an important role for
inflammatory mediators in the activation of proMMPs in
the endometrial extracellular matrix. In turn, activated
MMPs have been shown to modulate inflammatory proc-
esses, including the activity and mobilization of chemok-
ines and cytokines [44,45] thereby regulating the further
influx of inflammatory cells [11-16]. Therefore, MMPs
and inflammatory mediators are components of a com-
plex network governing uterine growth and remodeling,
as well as other normal and disease processes.
In the current study, we have developed a novel method
to quantitatively analyze transmission electron micro-
graphs to assess estrogen-induced endometrial collagen
remodeling in the OVX immature rat model along a time
course that includes both the hypertrophic and hyperplas-
tic phases of uterine growth. Using matrix collagen den-
sity as a quantitative and reliable endpoint, we specifically
determined that estrogen-induced stromal matrix remod-
eling is MMP-dependent. We further characterized hor-
mone-regulated expression of MMP-3 (stromelysin-1),
MMP-7 (matrilysin), MMP-2 (gelatinase A), and MMP-9
(gelatinase B), four metalloproteinases believed to func-
tion prominently in various reproductive processes
[6,38], as well as the inflammatory mediators TNF-α and
MCP-1 along an extended post E2-treatment time course
to assess changes in tissue protease and inflammatory
potential through both the early hypertrophic and later
hyperplastic growth phases. In addition, we have investi-
gated the effect of the anti-inflammatory synthetic gluco-
corticoid dexamethasone on E2-induced stromal matrix
remodeling and MMP and inflammatory mediator expres-
sion to better understand the role of inflammation in the
tissue pathway linking estrogen receptor activation to
changes in tissue ultrastructure necessary for uterine
growth and remodeling.
Methods
Animal treatments and tissue preparations
All animal experiments were performed in compliance
with NIH standards as specified in the Guide for Care and
Use of Laboratory Animals (copyright 1996, National Acad-
emy of Sciences). Female Sprague-Dawley rats (Ace Ani-
mal Corp., Boyertown, PA) were ovariectomized at 21Reproductive Biology and Endocrinology 2009, 7:124 http://www.rbej.com/content/7/1/124
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days of age and allowed to recover for 3-5 days. For E2
time course experiments, animals were administered a
single physiological dose of E2 (40 μg/kg in a 0.9% NaCl,
0.4% EtOH vehicle) by intraperitoneal (i.p.) injection at
the indicated time intervals prior to tissue collection at
necropsy. This in vivo dose level of E2 has been shown to
induce changes in uterine wet weight, tissue architecture,
and gene expression characteristic of estrogen receptor
activation [1,46-48]. For all other experiments, animals
were i.p. administered a single 40 μg/kg bolus of E2 4 h
prior to tissue harvest, while control animals received
vehicle only in all studies. Batimastat was administered
i.p. at a dose level (BB-9; 40 mg/kg in a 1× PBS, 0.1%
Tween-20 vehicle) shown to be effective at inhibiting
MMPs in vivo [49] 4 h prior to E2 or saline control. Dex-
amethasone was administered i.p. at a dose level of 600
μg/kg in a 0.9% NaCl, 10% EtOH vehicle that has been
previously used in rodent studies to assess in vivo steroid
specific responses in the uterus [46-48]. Animals were
treated twice with dexamethasone (600 μg/kg) at 20 and
4 h before E2 or saline control administration to elicit
both early and late gene effects of the activated glucocor-
ticoid receptor (GR) that may affect uterine responsive-
ness to E2  via genomic or nongenomic mechanisms.
Batimastat was generously provided by GlaxoSmithKline,
while other treatment compounds were obtained from
Sigma-Aldrich (USA). Dose levels of all compounds were
administered at injection volumes of 1 ml/100 g body
weight. Inhibitor compounds were administered i.p., with
control animals receiving the corresponding vehicle solu-
tion i.p. at the same treatment times as inhibitor injec-
tions.
For uterine tissue collection at necropsy, animals were
euthanized by decapitation on the same day in accord-
ance with the specific treatment time interval and the tis-
sue was stripped of fat and mesentery, weighed, and the
horns separated. One horn from each animal was flash
frozen in liquid N2 and stored at -80°C for later RNA puri-
fication. For protein analyses, two isolated horns from dif-
ferent animals were pooled and fresh-processed for total
protein extraction. For transmission electron microscopy
analyses, tissues were immediately fixed in 2.5% glutaral-
dehyde in 0.1 M phosphate buffer.
Transmission electron microscopy (TEM)
Individual uteri were fixed in 2.5% glutaraldehyde in 0.1
M phosphate buffer, pH 7.4, and 2 mm-cross sections of
each uterine horn were cut and incubated overnight at
4°C in 2.5% glutaraldehyde in 0.1 M phosphate buffer.
Glutaraldehyde buffer was removed, and the samples
were rinsed three times (15' each) in 0.1 M phosphate
buffer. Samples were incubated in 1% osmium in 0.1 M
phosphate buffer, rinsed, and dehydrated in a series of
ethanol washes. Samples were incubated twice for 5' in
propylene oxide and then transferred to a rotor for 1 h at
room temperature in a 1:1 mixture of propylene oxide and
epon [47% Embed 812, 31% DDSA (dodenyl succinic
anhydride), 19% NMA (nadic methyl anhydride), 3%
BDMA (benzyldimethylamine)], followed by an over-
night incubation in 1:2 propylene oxide-epon, and finally
100% epon for 2-3 hrs. Individual uterine samples were
embedded in 100% epon in silicon flat embedding
molds, and capsules were polymerized in a 60°C oven for
over 48 hrs. Ultrathin transverse sections (70 nm) were
prepared using a diamond knife (Diatome) on a MT
6000-XL ultramicrotome, captured on 300-mesh copper
grids, and stained with 2% uranyl acetate. All reagents and
materials were obtained from Electron Microscopy Sci-
ences (Hatfield, PA).
A minimum of 3 blocks with tissue from different areas
along the length of each uterine horn were chosen at ran-
dom from a total pool of 5-6 blocks and were used to pre-
pare ultrathin sections to provide a comprehensive survey
of whole organ ultrastructure representatively. A mini-
mum of 6 transverse sections were prepared per tissue
block and viewed using a Hitachi 7600 microscope fitted
with an AMT digital camera. Visual analyses and micro-
graph surveys were restricted to the endometrial stromal
compartment at a minimum of 3 random sites within the
endometrium of each section so as to avoid bias. At each
random site within the endometrial stromal matrix com-
partment, 3-6 digital photomicrographs at 12,000× mag-
nification were taken. For quantitative analysis of collagen
density, the full area of photomicrographs was digitally
fitted with an 8 × 8 square grid containing a total of 64
cross-points, and each cross-point was evaluated to deter-
mine the structure that it overlaid. Image J software (NIH)
was used to quantify the total number of crossbars land-
ing on collagen fibrils (positive hits), and the values were
expressed as a ratio to the total number of crossbars to
determine a percent matrix density volume for each phot-
omicrograph. Stromal areas with a high percentage of col-
lagen fibrils cut in transverse were selected to best ensure
that quantitative crossbar analysis was not significantly
affected by dramatic differences in collagen fiber orienta-
tion. A total of 36-75 micrographs were analyzed per time
point or treatment condition. Values for all micrographs
for each animal were averaged, and statistical differences
between averages of each time point or treatment group
were analyzed using one-way ANOVA. Error bars on
graphs represent standard error, and a standard P value of
≤ 0.05 was considered significant.
RNA isolation and quantitative real-time PCR
For TaqMan®  quantitative real-time PCR analyses of
mRNA levels, total RNA was prepared individually from
the uterus of each rat. Each uterus was disrupted for 2-3
minutes in 0.75 mL QIAzol lysis reagent (Qiagen, Valen-Reproductive Biology and Endocrinology 2009, 7:124 http://www.rbej.com/content/7/1/124
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cia, CA) using a 5 mm bead in a TissueLyser (Qiagen-Ret-
sch). The homogenate was subjected to a 0.2 mL
chloroform extraction and centrifugation at 4°C for 15
min at 20,000 × g, and 0.35 mL aqueous phase was col-
lected for RNA purification using an RNeasy kit (Qiagen)
according to the manufacturer's protocol. Residual
genomic DNA was removed by on-column RNase-free
DNase treatment during RNA purification, and the RNA
concentration was adjusted to 0.05 mg/mL. Messenger
RNA levels were analyzed using quantitative real-time
PCR on an ABI Prism 7900 Sequence Detection System
and TaqMan® gene expression assays (Applied Biosystems,
Foster City, CA) for MMP-2 (Rn01538174_m1), MMP-3
(Rn00591740_m1), MMP-7 (Rn00563467_m1), MMP-9
(Rn00579162_m1), TNF-α (Rn01753871_m1), MCP-1
(Rn01456716_g1) and eukaryotic 18s rRNA
(Hs99999901_s1). To compare mRNA expression levels
among samples, mRNA for each gene of interest was nor-
malized to the expression of a housekeeping gene, 18s
rRNA, and differences in gene expression were calculated
as a fold change to the mean of the vehicle group.
Protein extraction, SDS-PAGE, and immunoblotting
Detailed methods for protein extraction, SDS-PAGE, and
immunoblotting have been described previously [46]. In
brief, 2-3 uterine tissues were pooled and homogenized in
50 mM Tris pH 7.5, 150 mM NaCl, 1 mM CaCl2, 0.05%
Brij 35, 1 mM PMSF, and 10 μg/ml leupeptin using a pol-
ytron homogenizer (Brinkman Instruments, Westbury,
NY). Homogenates were centrifuged at 15,000 × g for 30
minutes at 4°C and the supernatants removed and pro-
tein quantified. Extracted total protein (20 μg) samples
were loaded into the wells of a pre-cast gel (4-20% Tris-
HCl; BioRad, Hercules, CA) and resolved by electrophore-
sis in a Mini-Protein II module (BioRad) according to the
manufacturer's protocol. Resolved proteins were trans-
ferred to an Immobilon-P membrane (Millipore, Billerica,
MA), which was blocked (5% BSA in 1× Tris-buffered
saline + 0.1% Tween-20 + 2% normal goat serum) and
then incubated in a 1:2000 dilution of affinity-purified
polyclonal rabbit anti-MMP-2 IgG (Novus Biologicals, Lit-
tleton, CO; #NB200-193), anti-human MMP-7 IgG
(Lifespan Bioscience, Seattle, WA; #LS-B1237), anti-MMP-
3 IgG (Abcam, Cambridge, MA; #ab53015), anti-MMP-9
IgG (Abcam #ab7299), anti-TNF-α IgG (Cedarlane, Burl-
ington, NC; #CL9572AP), anti-MCP-1 IgG (Millipore,
Billerica, MA; #AB1834P) or monoclonal mouse anti-β
actin IgG (Abcam #ab6276) overnight in blocking solu-
tion at 4°C with gentle agitation. Membranes were
washed and incubated in a 1:10,000 dilution of secondary
HRP-conjugated goat α-rabbit IgG or α-mouse IgG (Jack-
son Immunologicals, West Grove, PA) in blocking solu-
tion and then washed and transferred to a solution of
SuperSignal Substrate reagents (Pierce/Thermo Scientific,
Rockford, IL) for enhanced chemiluminescent signal
detection, imaged, and analyzed using the FluorChem SA
system (Alpha Innotech, San Leandro, CA) and AlphaEase
FC software. Band intensities were measured as integrated
density volumes (IDV) and expressed as % of control lane
values for comparisons between treatment groups. Specif-
icity of bands identified using primary antibodies was
confirmed by exposing sample blots to either 2% normal
goat serum alone, secondary goat HRP-conjugated anti-
body in the absence of primary antibody, or normal rab-
bit IgG (Jackson Immunologicals) only prior to secondary
antibody incubation.
Gelatin zymography
Extracted total protein (20 μg) samples were mixed 1:1
with zymography sample buffer (Bio-Rad) and incubated
at room temperature for 10 min. Samples were loaded
into the wells of a pre-cast gel (10% gelatin, BioRad) and
resolved by electrophoresis in a Mini-Protein II module
(BioRad) under non-reducing conditions. Active human
MMP-2 (Calbiochem/EMD Biosciences, Gibbstown, NJ;
#PF023) was loaded in one lane of the gel as a control.
After electrophoretic separation, the gel was washed twice
for 30 minutes each in 1× renaturation buffer (Bio-Rad) at
room temperature (RT) with gentle agitation and then
incubated in 1× development buffer (Bio-Rad) for 30
minutes at RT. Fresh development buffer was added and
the gel incubated at 37°C for 18-24 hours. Developed gels
were stained with Coomassie Brilliant Blue R-250 (0.5%
in 30% methanol, 10% acetic acid) for 30 minutes at RT.
The gel was destained in 30% methanol, 10% acetic acid
until clear bands representing proteolytic areas were visu-
alized. Gels were visualized with the FluorChem SA sys-
tem (Alpha Innotech) and analyzed using AlphaEase FC
software. Band intensities were measured as integrated
density volumes (IDV) and expressed as % of control lane
values for comparisons between treatment groups.
Statistics
Data is represented as the average ± standard error of the
mean (SE). Data were analyzed initially via one-way
ANOVA followed by Tukey's Honestly Significant post-
comparison test to assess differences between treatment
groups. P values ≤ 0.05 were considered significantly dif-
ferent.
Results
E2 induces rapid remodeling of uterine stromal matrix 
ultrastructure
To better characterize previously described E2-induced
changes in uterine stromal collagen matrix remodeling
[1], we developed a novel method to quantitatively assess
changes in collagen fibril density using a grid overlay anal-
ysis of TEM photomicrographs (as described in Methods).
This method establishes matrix density as a quantifiable
endpoint for studies aimed at assessing changes in activityReproductive Biology and Endocrinology 2009, 7:124 http://www.rbej.com/content/7/1/124
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of matrix processing enzymes, including the MMPs,
induced by bioactive compounds and inhibitors in a very
precise and direct manner. We assessed collagen matrix
density using micrographs prepared from uterine sections
along the entire length of the uterine horn to best repre-
sent whole tissue architecture changes and over an
extended time course after administration of a single
physiological dose of E2 (40 μ/kg) to study stromal colla-
gen architecture throughout both the early hypertrophic
and latter hyperplastic phases of uterine growth. Qualita-
tive assessment of micrographs indicates that a dense
irregular organization of collagen fibers is clearly observed
within saline-treated tissues (0 h), but this organization
rapidly disappears such that a significant difference is evi-
dent within 45 minutes of hormone administration.
Matrix density reaches a low point by 4 h when only a few
isolated fibrils within the stromal compartment remain
(Figure 1). Quantitative analysis of collagen matrix den-
sity supports a significant decrease (~30% less than 0 h-
saline levels) within 45 minutes post-E2 treatment and a
continual decline over time, reaching its lowest value
(~70% less than 0 hr) at 4 h and remaining low through
the 24 h treatment interval (Figure 2).
Stromal matrix remodeling is dependent upon activity of 
MMPs
Upon establishing a quantitative method to assess
changes in stromal matrix density, we assessed effects of a
broad-range hydroxamate inhibitor of MMPs, batimastat
(40 mg/kg), on E2-induced matrix remodeling in OVX
animals (Figure 3) to better characterize the role of acti-
vated MMPs in hormone-stimulated collagen reorganiza-
tion. Matrix density was analyzed in saline- or batimastat-
pretreated animals 4 h after E2 administration, the time
point at which collagen density was observed to be at its
lowest after hormone treatment (Figures 1 and 2). Trans-
mission electron microscopy assessment (Figure 3) shows
that batimastat alone has no effect on the stromal colla-
gen network (Sal-Sal vs. Bat-Sal), but overall collagen den-
sity in batimastat-pretreated E2-induced animals (Bat-E2)
is significantly higher (~4-fold) compared to those receiv-
ing saline pretreatment and E2 treatment (Sal-E2), clearly
indicating that E2-induced uterine matrix remodeling is, at
least in part, dependent upon activated MMPs.
E2 induces transient upregulation of uterine MMP mRNA 
and protein
While effects of ovarian hormones on uterine MMP
expression have been studied under a variety of condi-
tions in the rodent and human, we chose to fully charac-
terize temporal changes in expression of MMP-2, MMP-3,
MMP-7, and MMP-9 induced specifically by E2 in the
immature OVX rat and to examine any correlation in
enzyme levels with the time course of collagen matrix
remodeling. The enzymes surveyed include those known
to be expressed by uterine epithelial (MMP-7) as well as
stromal (MMP-2, MMP-3 and MMP-9) cells [50]. In addi-
tion, collagen substrates for MMP-2 (I, III, IV, V, VII, X,
XI), MMP-3 (II, III, IV, V, VII, IX, X), MMP-7 (I, IV, X), and
MMP-9 (IV, V, VII, XIV) have been characterized in vitro
[50]. Levels of mRNA and protein for these MMPs were
assessed following saline treatment (0 h) and at 5 inter-
vals (4-72 h) post-E2 administration. While mRNA tran-
scripts for all MMPs analyzed (Figure 4A) are detected in
the uterus in saline control tissues (0 h), significant
increases in transcript levels are induced within 4 h by E2
treatment for MMP-3, MMP-7, and MMP-9. Of these
enzymes, the fold induction (~150-fold) for MMP-7 is
clearly the most robust (Figure 4). In contrast, levels of
MMP-2 mRNA do not increase until later in the time
course, with peak fold induction (~7 fold) occurring at 48
h post-hormone administration, thereby placing it on a
different time line of regulation compared to MMP-3,
MMP-7, and MMP-9. Upregulation of mRNA for all
enzymes is transient, as transcript levels decline signifi-
cantly and return to control values by 72 h.
Western blot analyses (Figure 4B) were completed to
determine if uterine MMP protein changes in correlation
with the mRNA induction profiles for each enzyme.
MMP-2, MMP-3, and MMP-9 are detected in saline tissues
and increase after E2  treatment in accord with peak
changes in mRNA for each gene. Levels of the latent (~72
kDa) form of MMP-2 increase significantly within 4 h, but
peak changes in latent and active (~64 kDa) protein do
not occur until ~24-48 h post-E2 treatment (Figure 4B),
which correlates temporally with the peak in mRNA con-
tent (Figure 4A). Tissue levels of MMP-3 (~62 kDa) and
MMP-9 (~90 kDa) increase within 4 h of E2 treatment
(Figure 4B) in conjunction with changes in mRNA (Figure
4A). While levels of MMP-9 decline over time, reaching
control values within 24 h, MMP-3 protein remains ele-
vated through 72 h, although the mRNA for this enzyme
reaches control levels within 24 h after hormone admin-
istration (Figure 4A). This indicates that MMP-3 protein is
temporally stabilized and levels do not decline to those
observed prior to E2  stimulation. Latent MMP-7 (~29
kDa) is not detectable in control tissues (0 h), but levels
of the enzyme increase significantly by 4 h post-E2 treat-
ment, then decline over time to return to control values by
48 h (Figure 4B) in correlation to the temporal pattern of
mRNA expression (Figure 4A). Upregulation of MMP-3,
MMP-7, and MMP-9 protein expression 4 h post-E2 indi-
cates that these enzymes are in fact elevated rapidly by
hormone treatment with peak increases in protein con-
tent occurring at the time point when stromal collagen
matrix is lowest (Figures 1 and 2).
E2-induced changes in activity of the gelatinase enzymes
were assessed via gelatin zymography (Figure 5) to con-Reproductive Biology and Endocrinology 2009, 7:124 http://www.rbej.com/content/7/1/124
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Transmission electron microscopy analysis of ultrastructural changes in the uterine stromal matrix in response to E2 treatment Figure 1
Transmission electron microscopy analysis of ultrastructural changes in the uterine stromal matrix in 
response to E2 treatment. Representative TEM micrographs of the endometrial stroma of animals administered E2 (40 μg/
kg) at the indicated time points prior to tissue collection. Micrographs shown are representative of typical observations from a 
total of 54 to 72 micrographs analyzed from 4-5 animals per time point; C = Collagen, S = Stromal cell, scale bar = 0.5 μm.Reproductive Biology and Endocrinology 2009, 7:124 http://www.rbej.com/content/7/1/124
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firm overall protein expression levels observed via West-
ern blot. The major bands representing gelatin-degrading
activity were identified as active MMP-9 (~90 kDa) and
latent and active MMP-2 (~72 kDa and 64 kDa, respec-
tively). Overall activity of MMP-2 was greater than that of
MMP-9 based upon band intensities. Levels of active
MMP-2 decrease slightly within 4-12 h of hormone treat-
ment (Figure 5). However, both latent and active forms of
MMP-2 increase by 48 h post-E2 treatment, with peak
activity correlating temporally with the highest level of
total protein observed via Western blot (Figure 4). Activity
of MMP-9 increases significantly at 4 h post E2-treatment
(Figure 5) also corresponding to the time point when total
protein levels are highest (Figure 4). Activity of MMP-3
and MMP-7 was assessed via casein gel zymography, how-
ever sensitivity of the assay was not sufficient to permit
quantitative analysis (data not shown).
E2 induces transient upregulation of the pro-inflammatory 
cytokine TNF-  and the  -chemokine MCP-1
E2-induced changes in expression of the pro-inflamma-
tory cytokine, TNF-α, and the β-chemokine MCP-1, were
assessed over the biphasic growth response to better char-
acterize the tissue inflammatory response and to compare
changes temporally with matrix processing and MMP
expression. Levels of TNF-α mRNA and protein transiently
increase with a peak in expression occurring 4 h after hor-
mone treatment (Figure 6A). TNF-α mRNA increases
nearly 25 fold at 4 h and remains elevated through 12 h
post-E2 treatment before declining to control values by 48
h. Western blot analysis (Figure 6B) identified the homo-
trimeric form of the protein (~51 kDa) as well as lower
MW forms. Analysis of the receptor-ligand homotrimeric
form shows slight elevation of protein early (1-2 h) with
maximum levels occurring at 4 and 12 h post E2 adminis-
tration (Figure 6B), correlating temporally to the major
time points of mRNA elevation. This pattern clearly indi-
cates a potent overall enhancement of tissue levels of TNF-
α expression, most notably during the early hypertrophic
period of uterine growth following hormone treatment.
MCP-1 mRNA expression is also significantly upregulated
(~80 fold) 4 h post-E2 treatment. While mRNA levels
return to control values within 24 h, MCP-1 protein
increases by 4 h but remains elevated through 48 h before
returning to control tissue levels 72 h post-treatment (Fig-
ure 6B). Western blot analysis detects a higher MW form
of MCP-1 (~20 kDa) which may represent an intact bioac-
tive form of the chemokine, as well as a lower MW form
(~16 kDa) which may represent a proteolytic and recep-
tor-inactive product (Figure 6B). Blot analysis indicates
that levels of the higher MW MCP-1 product peak at 4 h
whereas the lower MW product peaks at ~24 h post treat-
ment. E2 treatment thus rapidly increases levels of two
potent pro-inflammatory chemicals, TNF-α and MCP-1,
and the induction correlates temporally with the hyper-
trophic phase of tissue growth, which is characterized by
tissue edema and stromal matrix remodeling.
Dexamethasone pretreatment inhibits E2-induced uterine 
growth and changes in uterine tissue ultrastructure
Because peak changes in matrix density and cytokine
expression correlate temporally with the hypertrophic
phase of E2-induced uterine growth, it was of interest to
assess the effects of the anti-inflammatory synthetic gluco-
corticoid, dexamethasone (600 μg/kg) on this inflamma-
tory-like response. Dexamethasone pretreatment alone
induces a decrease in uterine wet weight and significantly
inhibits the typical increase in uterine wet weight effected
by E2 (Figure 7) in a manner consistent with previously
published reports [34]. With respect to stromal matrix
density, dexamethasone alone produces both a qualitative
and quantitative change in matrix structure (Figure 8);
there is a noticeable and statistically significant increase in
stromal matrix density as compared to saline control ani-
mals (Dex-Sal vs. Sal-Sal). This indicates that dexametha-
sone modulates stromal matrix remodeling so as to
generate a more densely organized collagen architecture
in the immature uterus. In addition, dexamethasone pre-
treatment inhibits E2-induced matrix remodeling; stromal
collagen density is much higher (~4-fold) in dexametha-
sone-pretreated (Dex-E2) animals as compared to saline-
pretreated E2-challenged animals (Sal-E2). Quantitative
analysis of collagen density indicates that collagen levels
are equivalent in the Dex-E2 as compared to control ani-
Quantitative analysis of E2-induced changes in uterine stro- mal matrix density Figure 2
Quantitative analysis of E2-induced changes in uter-
ine stromal matrix density. Endometrial collagen density 
values represent mean percent volume per time point calcu-
lated from micrograph analysis; one-way ANOVA, error bars 
represent ± SE for 4-5 animals per time point, total micro-
graphs analyzed per time point range from 54 to 72; *P < 
0.05 compared to 0 h saline control.Reproductive Biology and Endocrinology 2009, 7:124 http://www.rbej.com/content/7/1/124
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Batimastat effects on E2-induced changes in uterine stromal matrix density Figure 3
Batimastat effects on E2-induced changes in uterine stromal matrix density. Transmission electron microscopy 
analysis of endometrial stroma from animals pretreated with saline or batimastat (Bat: 40 mg/kg) 4 h prior to administration of 
E2 or saline injected 4 h prior to tissue collection. Panel A: Representative TEM micrographs of stromal matrix. Micrographs 
shown are typical from a total of 36 to 54 micrographs analyzed from 3-4 animals per treatment group; C = Collagen, S = Stro-
mal cell, scale bar = 0.5 μm. Panel B: Quantified endometrial collagen density; one-way ANOVA, error bars represent ± SE for 
3-4 animals per treatment group, total micrographs analyzed per time point range from 36 to 54; *P < 0.05 compared to saline 
control (Sal-Sal).Reproductive Biology and Endocrinology 2009, 7:124 http://www.rbej.com/content/7/1/124
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Temporal changes in uterine MMP mRNA and protein in response to E2 Figure 4
Temporal changes in uterine MMP mRNA and protein in response to E2. Uterine mRNA analysis via TaqMan® real-
time PCR (panel A) and protein analysis via Western blot (panel B) are shown for MMP-2, MMP-3, MMP-7 and MMP-9 from 
uteri of OVX rats 0-72 h after treatment with saline (0 h control) or E2 (40 μg/kg). Messenger RNA values (panel A) represent 
mean ± SE, n = 6 tissues per group; one way ANOVA, *P < 0.05 compared to 0 h time point. Western blot images (panel B) 
are representative of a minimum of 3 blots using 3 separate pools of total protein extracted from different animals. Intensities 
of protein bands were quantitated using AlphaEase FC software (Alpha Innotech) as described in the Methods and values for 
each time point expressed as percent of saline control (100%). Quantitative data (panel B) reflect average band intensity values 
± SE measured from ≥ 3 blots with total protein extracted from different animals in 2 separate experiments; one way ANOVA, 
*P < 0.05 compared to 0 h time point. IDV = integrated density value. Western blot analysis of β-actin as a control for gel load-
ing is shown for the protein samples used to assess MMP protein for the blots above.Reproductive Biology and Endocrinology 2009, 7:124 http://www.rbej.com/content/7/1/124
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mals (Sal-Sal). It should be noted that the magnitude of
inhibition of collagen matrix remodeling induced by E2 is
smaller in dexamethasone pretreated animals (Figure 8
bottom, Dex-E2 vs. Sal-E2) indicating that it is not fully
efficacious at inhibiting the E2 response.
Dexamethasone pretreatment modifies E2-induced 
changes in uterine MMP expression
In light of the inhibitory effect on E2-induced stromal
matrix remodeling (Figure 8), MMP mRNA and protein
levels were analyzed in animals pre-treated with dexame-
thasone. Dexamethasone treatment increases expression
of MMP-3 mRNA, when compared to levels in control ani-
mals (Figure 9A; Dex-Sal vs. Sal-Sal). In addition, dexam-
ethasone does not inhibit the E2-induced increase in
MMP-3 mRNA (Figure 9A; Dex-E2 vs. Sal-E2). Levels of
mRNA in Dex-E2 animals are not significantly different
from those in Dex-Sal controls, indicating that dexameth-
asone induction of mRNA expression for MMP-3 is not
modified in the presence of E2. Transcript levels for MMP-
7 and MMP-9 are unaffected by pretreatment (Figure 9A,
Dex-Sal vs. Sal-Sal), although dexamethasone pretreat-
ment does significantly inhibit the E2-induced upregula-
tion of mRNA for these two enzymes (Dex-E2 vs. Sal-E2).
Dexamethasone does not induce a change in MMP-2
mRNA (Figure 9A); however, effects on the E2-induced
upregulation of MMP-2 mRNA were not assessed since
only the 4 h post-hormone treatment time point was stud-
ied, and transcript levels for this enzyme do not signifi-
cantly increase until 48 h post-E2 administration (Figure
4A).
Western blot analyses of MMP protein levels support the
effects of dexamethasone on mRNA expression. Pretreat-
ment inhibits E2-induced upregulation of protein expres-
sion for MMP-3, MMP-7, and MMP-9 (Figure 9B; Dex-E2
vs. Sal-E2). Interestingly, levels of MMP-3 protein do not
increase in response to dexamethasone pretreatment
despite evidence of an elevation of tissue mRNA (Figure
9A). Gelatin zymography shows that dexamethasone pre-
Temporal changes in gelatinase activity in response to E2 Figure 5
Temporal changes in gelatinase activity in response to E2. Gelatin zymography analysis is shown for MMP-2 and MMP-
9 activity from uteri of OVX rats 0-72 h after treatment with saline (0 h control) or E2 (40 μg/kg). Zymogram (top) is repre-
sentative of 6 gels using 3 separate pools of total protein extracted from different animals. Quantitative data (bottom) repre-
sents analysis of band intensity using AlphaEase FC software (Alpha Innotech) as described in the Methods; one way ANOVA, 
values represent mean ± SE for 6 gels. *P < 0.05 compared to 0 h time point.Reproductive Biology and Endocrinology 2009, 7:124 http://www.rbej.com/content/7/1/124
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Temporal changes in uterine cytokine mRNA and protein in response to E2 Figure 6
Temporal changes in uterine cytokine mRNA and protein in response to E2. Uterine mRNA analysis via TaqMan® 
real-time PCR (panel A) and protein analysis via Western blot (panel B) are shown for TNF-α and MCP-1 from uteri of OVX 
rats 0-72 h after treatment with saline (0 h control) or E2 (40 μg/kg). Messenger RNA values (panel A) represent mean ± SE, n 
= 5-6 per group; one way ANOVA, *P < 0.05 compared to 0 h time point. Western blots images shown (panel B) are repre-
sentative of a minimum of 3 blots using 3 separate pools of total protein extracted from different animals in 2 separate experi-
ments. Intensities of protein bands were quantitated using AlphaEase FC software (Alpha Innotech) as described in the 
Methods and values for each time point expressed as percent of saline control (100%). Quantitative data (panel B) reflect aver-
age band intensity values ± SE measured from ≥ 3 blots with total protein extracted from different animals in 2 separate exper-
iments; one way ANOVA, *P < 0.05 compared to 0 h time point. IDV = integrated density value. Western blot analysis of β-
actin as a control for gel loading is shown for the protein samples used to assess TNF-α and MCP-1 protein for the blots 
above.Reproductive Biology and Endocrinology 2009, 7:124 http://www.rbej.com/content/7/1/124
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treatment did not affect activity of MMP-2 or MMP-9 (Fig-
ure 10), although dexamethasone pretreatment does
decrease the E2-induced upregulation of MMP-9 total pro-
tein levels (Figure 9B). Because full activity of MMPs may
not be recovered as a result of refolding of the enzymes
after electrophoresis in gel zymography [51], it is unclear
whether dexamethasone affects levels of active MMP-9 in
vivo.
Dexamethasone pretreatment affects E2-induction of 
uterine MCP-1 and TNF-  expression
Dexamethasone potently inhibits the E2-induced upregu-
lation of MCP-1 mRNA and protein observed at 4 h post-
hormone treatment (Figure 11). However, pretreatment
does not affect E2-induced upregulation of TNF-α mRNA
(Figure 11A), though it does decrease protein content
(Figure 11B).
Discussion
An examination of tissue responses in the E2-treated OVX
rat provides an opportunity to study selective effects of the
hormone that can be defined in the temporal context of
the hypertrophic and hyperplastic growth responses. In
this model, E2 induces uterine growth that is characterized
by changes in endometrial tissue architecture and gene
expression. We used TEM analysis to more specifically
assess changes in stromal collagen matrix quantitatively. A
significant decrease in matrix density is observed as early
as 45 minutes and reaches its lowest value, with an
approximate 70% reduction of the original collagen net-
work, at 4 hours post-hormone treatment, coinciding
with the peak time point of uterine hypertrophy. This
indicates that activation of matrix-processing enzymes is
extremely rapid and implies regulation of inherent pro-
teases through an estrogen receptor (ER)-mediated path-
way.
Pretreatment with the broad-range MMP inhibitor batim-
astat effectively ablates E2-induced changes in stromal
ultrastructure supporting a critical role for these enzymes
in tissue remodeling. These results differ from those by
Kaitu'u and colleagues [38], who reported that batimastat
reduced MMP activity but did not alter endometrial break-
down or repair as assessed through light microscopy in a
mouse decidualization model. The contrasting results
may reflect a difference in matrix processing during E2-
specific induction of tissue growth in the immature uterus
as compared to tissue regression following progesterone
withdrawal in a decidualization model. In addition, anal-
ysis of fine matrix structure and density using quantitative
TEM provides a more sensitive measure of changes in col-
lagen organization indicative of tissue remodeling as
compared to qualitative assessment of tissue appearance
via light microscopy [46].
While a number of MMPs are known to be expressed in
cell-type as well as cycle-specific patterns in the uterus
[2,5,50], E2-specific regulation in an OVX rodent model
has been studied in vivo for only a few [19]. Using this
model we show that expression of MMP-3, MMP-7, and
MMP-9 is upregulated at both RNA and protein level early
within the E2-induced growth response correlating with
the time point where stromal collagen matrix density
reaches its lowest point (4 h). While substrates for these
enzymes include fibrillar, fibril-associated, and network
forming collagens [50], in vivo substrates are unknown.
Therefore, although expression correlates with maximum
matrix remodeling temporally, we cannot conclude that
these particular proteases are directly causative. As an epi-
thelial cell expressed protease, MMP-7 is likely not criti-
cally involved in stromal matrix processing directly,
whereas MMP-3 and MMP-9 are known to be expressed
by stromal cells or infiltrating leukocytes [50]. Expression
of MMP-2 increases most significantly later in the growth
response (48 h) suggesting a complex level of regulation
that may involve E2-triggered production of signal com-
pounds which, in turn, enhance MMP-2 production.
Interestingly, tissue levels of MMP-3 protein also remain
elevated late in the growth response (24-72 h), indicating
extended in-tissue stabilization of this enzyme. The over-
all elevation of MMP-2 and MMP-3 content late, as com-
pared to MMP-7 and MMP-9 protein which peak early in
the growth response, implies alternate temporal functions
for tissue MMPs that may include activation of matrix
processing during both tissue growth and regression
phases. While providing important insight into the E2-
Dexamethasone effects on uterine wet weights Figure 7
Dexamethasone effects on uterine wet weights. Ani-
mals were pretreated with dexamethasone (Dex: 600 μg/kg) 
or saline 20 h and 4 h prior to administration of E2 or saline 
injected 4 h before tissue collection. Values represent mean 
± SE for 12-14 animals per treatment group; one way 
ANOVA, * P < 0.05 compared to saline control (Sal-Sal), ** P 
< 0.05 compared to E2 control (Sal-E2).Reproductive Biology and Endocrinology 2009, 7:124 http://www.rbej.com/content/7/1/124
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Effects of dexamethasone pretreatment on E2-induced changes in uterine stromal matrix density Figure 8
Effects of dexamethasone pretreatment on E2-induced changes in uterine stromal matrix density. Transmission 
electron microscopy analysis of endometrial stroma from animals pretreated with saline or dexamethasone (Dex: 600 μg/kg) 
20 h and 4 h prior to administration of E2 or saline injected 4 h prior to tissue collection. Panel A: Representative TEM micro-
graphs of stromal matrix. Micrographs shown are typical from a total of 54 to 70 images analyzed from 3-4 animals per treat-
ment group; C=Collagen, scale bar = 0.5 μm. Panel B: Quantified endometrial collagen density values representing mean 
percent volume for n = 3-4 animals per treatment group, total micrographs analyzed per group range from 54 to 70; one-way 
ANOVA, error bars represent ± SE; *P < 0.05 compared to saline control (Sal-Sal), **P < 0.05 compared to E2 control (Sal-E2).Reproductive Biology and Endocrinology 2009, 7:124 http://www.rbej.com/content/7/1/124
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Dexamethasone effects on E2-induced changes in MMP mRNA and protein Figure 9
Dexamethasone effects on E2-induced changes in MMP mRNA and protein. Uterine mRNA analysis via TaqMan® 
real-time PCR (panel A) and protein analysis via Western blot (panel B) are shown for MMP-2, MMP-3, MMP-7 and MMP-9 
from animals pretreated with saline or dexamethasone (Dex: 600 μg/kg) 20 h and 4 h prior to administration of E2(40 μg/kg) or 
saline given 4 h before tissue collection. Messenger RNA values (panel A) represent mean ± SE, n = 5-6 per group; one way 
ANOVA, *P < 0.05 compared to saline control (Sal-Sal), **P < 0.05 compared to E2 control (Sal-E2). Blot images shown (panel 
B) are representative of a minimum of 3 blots using 3 separate pools of total protein extracted from different animals. Intensi-
ties of protein bands were quantitated using AlphaEase FC software (Alpha Innotech) as described in the Methods and values 
for each time point expressed as percent of saline control (100%). Quantitative data (panel B) reflect average band intensity 
values ± SE measured from ≥ 3 blots with total protein extracted from different animals in 2 separate experiments; one way 
ANOVA, *P < 0.05 compared to saline control (Sal-Sal), **P < 0.05 compared to E2 control (Sal-E2). IDV = integrated density 
value. Western blot analysis of β-actin as a control for gel loading is shown for the protein samples used to assess MMP protein 
for the blots above.Reproductive Biology and Endocrinology 2009, 7:124 http://www.rbej.com/content/7/1/124
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triggered response at the whole tissue level, our analysis of
changes in MMP mRNA and protein content does not
define stromal-specific changes in enzyme content and
activity. Future studies to analyze MMP activity via in situ
zymography and mRNA expression using laser capture
microdissection and subsequent gene profiling would
provide a more precise window into the stromal tissue
response.
While we observed transient upregulation of MMP-2 and
MMP-9 mRNA and protein expression in response to E2 in
the OVX immature rat uterus, Zhang and colleagues [19]
did not observe an effect of E2 on MMP-2 mRNA levels in
the OVX adult mouse through 24 h post-hormone treat-
ment, though they did observe a decrease in MMP-9
mRNA, but not protein activity, 4-8 h post-treatment.
Since we observe peak changes in MMP-2 mRNA expres-
sion at 48 h after E2 administration, it is unclear if a simi-
lar response would be evident in an OVX adult model as
that time point was not assessed [19]. In contrast, our
analysis of MMP-9 mRNA protein via both Western blot
and zymography clearly shows upregulation by 4 h post-
E2 administration. Data inconsistencies may reflect differ-
ences in rodent model (mouse vs. rat) or in tissue respon-
siveness between the immature (first time hormone
exposure) as opposed to an adult (hormone-primed)
uterus.
A variety of inflammatory mediators [8,9,40,52,53] have
been shown to regulate expression and activity of MMPs,
and, E2 is known to induce an acute inflammatory-like
response within the uterus [54]. We show that E2 induces
potent and rapid upregulation of TNF-α, with peak
increases in mRNA and protein occurring at the time
point where MMP expression and stromal matrix process-
ing are upregulated (4 h). It is difficult to understand the
exact role of TNF-α expression in E2-induced uterine
matrix remodeling or in MMP gene transcription as this
bioactive compound is expressed in tissues and held in an
inactive state through cell surface or extracellular matrix-
binding interactions. Although ADAM-17 (TACE) is the
best characterized TNF-α sheddase, MMP-2, MMP-3,
MMP-7, and MMP-9 have been shown to release TNF-α
from the cell surface in a similar mechanism [13,45]. Pro-
tease-mediated shedding of TNF-α may induce signal
pathway activation that precedes an overall upregulation
of mRNA and protein expression for this inflammatory
mediator, thus analysis of expression alone is not a full
indicator of TNF-α activity in vivo. A study of E2-induced
changes in activity of the TNF-α pathway, including acti-
vation of NF-κB, will be important for a better under-
Effect of dexamethasone on E2-induced changes in gelatinase activity Figure 10
Effect of dexamethasone on E2-induced changes in gelatinase activity. Gelatin zymography analysis is shown for 
MMP-2 and MMP-9 activity from animals pretreated with saline or dexamethasone (Dex: 600 μg/kg) 20 h and 4 h prior to 
administration of E2 (40 μg/kg) or saline given 4 h before tissue collection. Zymogram (top) is representative of 6 gels using 3 
separate pools of total protein extracted from different animals. Quantitative data (bottom) represents analysis of band inten-
sity using AlphaEase FC software (Alpha Innotech) as described in the Methods; one way ANOVA, values represent mean ± SE 
for 6 gels. *P < 0.05 compared to saline control (Sal-Sal).Reproductive Biology and Endocrinology 2009, 7:124 http://www.rbej.com/content/7/1/124
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Dexamethasone effects on E2-induced changes in cytokine mRNA and protein Figure 11
Dexamethasone effects on E2-induced changes in cytokine mRNA and protein. Uterine mRNA analysis via Taq-
Man® real-time PCR (panel A) and protein analysis via Western blot (panel B) are shown for TNF-α and MCP-1 from animals 
pretreated with saline or dexamethasone (Dex: 600 μg/kg) 20 h and 4 h prior to administration of E2(40 μg/kg) or saline given 
4 h before tissue collection. Messenger RNA values (panel A) represent mean ± SE, n = 5-6 per group; one way ANOVA, *P < 
0.05 compared to saline control (Sal-Sal). Western blot images shown (panel B) are representative of a minimum of 3 blots 
using 3 separate pools of total protein extracted from different animals in 2 separate experiments. Intensities of protein bands 
were quantitated using AlphaEase FC software (Alpha Innotech) as described in the Methods and values for each time point 
expressed as percent of saline control (100%). Quantitative data (panel B) reflect average band intensity values ± SE measured 
from ≥ 3 blots with total protein extracted from different animals in 2 separate experiments; one way ANOVA, *P < 0.05 com-
pared to saline control (Sal-Sal), **P < 0.05 compared to E2 control (Sal-E2). IDV = integrated density value. Western blot anal-
ysis of β-actin as a control for gel loading is shown for the protein samples used to assess TNF-α and MCP-1 protein for the 
blots above.Reproductive Biology and Endocrinology 2009, 7:124 http://www.rbej.com/content/7/1/124
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standing of the role of this inflammatory agent as a critical
regulator of MMP expression in the estrogen response
pathway.
Expression of the β-chemokine MCP-1 (CCL2), a potent
chemoattractant for macrophages, T cells, basophils, and
mast cells is also potently upregulated at 4 h. Enhanced
production of MCP-1 is known to occur during the prolif-
erative phase of the cycling uterus and, expression is stim-
ulated by TNF-α [55-57]. The timing of highest tissue
levels of MCP-1 at 4 h correlates with the peak in expres-
sion of TNF-α, suggesting that it may be a key signal com-
ponent for inducing leukocyte influx by creating in-tissue
gradients of chemokines, like MCP-1, which are triggered
early during the hypertrophic phase of uterine growth.
MCP-1 is also a substrate for a variety of MMPs, including
MMP-3 [14], and protease-mediated processing has been
shown to inhibit bioactivity of β-chemokines, thereby reg-
ulating the timing and intensity of leukocyte influx once
an inflammatory response is underway [14,44,45,58].
Correlations between E2-regulated uterine growth,
inflammation, and MMP expression and activation in the
immature OVX uterus led us to investigate the effects of
dexamethasone, the synthetic glucocorticoid and anti-
inflammatory agent. We show that dexamethasone modi-
fies stromal matrix collagen density and, pretreatment
with dexamethasone effectively inhibits E2-induced colla-
gen remodeling. These data suggest that the regulation of
collagen density is under the influence of activated gluco-
corticoid-receptor (GR) and, implicates the MMP system
because dexamethasone is known to inhibit MMP expres-
sion [59]. Dexamethasone effects on MMP expression
however, are complex. Of the MMPs that are upregulated
4 h post-E2  treatment, dexamethasone pretreatment
inhibits both MMP-7 and MMP-9 mRNA and protein
expression but does not inhibit the E2-induced increase in
MMP-3 mRNA or protein.
In addition to effects on the MMP system, dexamethasone
is also known to block the pro-inflammatory effects of E2
in the uterus [34]. Glucocorticoids have been shown to
suppress expression of chemoattractant chemokines, such
as MCP-1 [60], and possibly, through inhibition of MMP
expression, may decrease sheddase activity and ECM
processing important for liberation of inherent bioactive
agents, including TNF-α, that activate signal pathways to
enhance inflammatory processes. Our data clearly show
that dexamethasone has no effect on TNF-α or MCP-1
mRNA or protein expression. However, dexamethasone
pretreatment potently inhibits E2-induced upregulation of
MCP-1 mRNA and protein expression and decreases levels
of TNF-α protein observed at 4 h post-treatment, thereby
supporting its effects as a suppressor of both inflamma-
tory signaling as well as matrix remodeling.
Collectively our data show that E2-induced endometrial
matrix remodeling, production of MMPs, and inflamma-
tory mediators correlate temporally with the early phase
of uterine growth which is hypertrophic and inflamma-
tory-like in nature. Dexamethasone as an anti-inflamma-
tory agent inhibits these processes however, because
activated GR can directly modify expression of MMPs and
inflammatory agents such as MCP-1, further investigation
is necessary to determine the role of inflammation itself
on matrix remodeling. One model of the E2 response
would be that hormone-triggered rapid activation of
inherent proteases leads to matrix processing that liber-
ates bound inflammatory mediators like TNF-α, thereby
producing inflammation and leukocyte influx. Alterna-
tively, rapid E2-induced inflammation triggered by ER sig-
nal pathways and production of paracrine regulators like
prostaglandins would drive influx of leukocytes which, in
turn, activate inherent proteases to effect changes in stro-
mal matrix architecture necessary for tissue expansion as
growth proceeds. Evidence indicates that infiltrating leu-
kocytes contribute to tissue protease density [8,9,61-63]
and neutrophilic depletion clearly inhibits endometrial
repair in the mouse [25]. Further studies must focus upon
the timing of E2-induced changes in expression and activ-
ity of inflammatory mediators and leukocyte influx in
relation to matrix processing to more clearly delineate the
E2 response pathway. In addition, the use of other kinds of
anti-inflammatory agents such as COX inhibitors, that
would specifically inhibit production of prostaglandins,
will also provide a better understanding of the role of
inflammatory reactions per se on matrix processing.
Conclusion
This study using the OVX immature rat model contributes
to a better understanding of specific regulation of MMP
expression and endometrial tissue remodeling induced by
E2 and the counter-regulatory effects of dexamethasone.
We have established a novel assay system for measuring
stromal collagen matrix density as a reliable and specific
endpoint for assessment of matrix remodeling. The data
demonstrate that E2-regulated endometrial remodeling is
rapid in onset (<1 hour) and peak changes in expression
of MMP-3, -7, and -9 and the inflammatory mediators
TNF-α and MCP-1, correlate temporally with the period of
lowest stromal collagen density during uterine tissue
hypertrophy (4 h). Our survey of changes in expression of
MMPs and inflammatory mediators provides the ground-
work for further studies of molecular triggers that link ER
activation with inflammatory-like responses and matrix
processing in the uterus.
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